Qiming Leads $20M Round In Chinese Start-Up Connect Biopharmaceuticals

Qiming Venture Capital has led a US$20 million series A round in Connect Biopharmaceuticals Ltd., a clinical-stage company developing immune modulators for autoimmune diseases and cancer treatment.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

LEAVE A REPLY